OralDosed ingredientTherapeutic flag Cosmetic cross-reference

Topiramate

CAS 97240-79-4

Topiramate (CAS 97240-79-4) is a Phase 4 pharmaceutical compound with 28 bioactivity targets and 7,885 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

7,885

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Topiramate

CAS Number

97240-79-4

UNII

0H73WJJ391

InChIKey

KJADKKWYZYXHBB-XBWDGYHZSA-N

ChEMBL ID

CHEMBL220492

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

Synonyms and normalized names

Topamax

dosed ingredientnatural productoraltherapeutic flag

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)

Approved or marketed human pharmaceutical use is represented in the source phase field.

ChEMBL CHEMBL220492 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 44 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	Ki	3808.1211869436206 nM	335	-
-	AC50	20711.5168 nM	125	-
-	IC50	16773.624705882354 nM	16	-
-	Kd	154.8 nM	4	-
-	Potency	2.8 nM	1	-
Sodium channel protein type 5 subunit alpha Ion channel	BLOCKER	-	-	Homo sapiens
Sodium channel protein type 1 subunit alpha Ion channel	BLOCKER	-	-	Homo sapiens
Nuclear receptor subfamily 1 group I member 2 Nuclear hormone receptor	-	-	-	Homo sapiens
Carbonic anhydrase 2 Enzyme	Ki	8.3	-	Homo sapiens
Carbonic anhydrase 1 Enzyme	Ki	6.6	-	Homo sapiens
Carbonic anhydrase 4 Enzyme	Ki	5.31	-	Homo sapiens
Carbonic anhydrase 9 Enzyme	Ki	7.24	-	Homo sapiens
Carbonic anhydrase 12 Enzyme	Ki	8.42	-	Homo sapiens
Carbonic anhydrase 5A, mitochondrial Enzyme	Kd	7.6	-	Homo sapiens
Carbonic anhydrase 5B, mitochondrial Enzyme	Ki	7.52	-	Homo sapiens
Carbonic anhydrase 7 Enzyme	Ki	9.06	-	Homo sapiens
Carbonic anhydrase Enzyme	Ki	6.76	-	Helicobacter pylori (strain ATCC 700392 / 26695)
Carbonic anhydrase 6 Enzyme	Ki	7.35	-	Homo sapiens
Carbonic anhydrase 14 Enzyme	Ki	5.84	-	Homo sapiens
Carbonic anhydrase 13 Enzyme	Ki	7.33	-	Mus musculus
Carbonic anhydrase 4 Enzyme	Ki	7.27	-	Bos taurus
Sodium channel protein type 2 subunit alpha Ion channel	IC50	4.01	-	Rattus norvegicus
Carbonic anhydrase 2 Enzyme	IC50	5.85	-	Rattus norvegicus
Carbonic anhydrase Enzyme	Ki	6.92	-	Methanosarcina thermophila
Carbonic anhydrase Enzyme	Ki	4.63	-	Methanothermobacter thermautotrophicus (strain ATCC 29096 / DSM 1053 / JCM 10044 / NBRC 100330 / Delta H)
Carbonic anhydrase 13 Enzyme	Ki	7.33	-	Homo sapiens
Carbonic anhydrase 15 Enzyme	Ki	7.11	-	Mus musculus
Carbonic anhydrase Enzyme	Ki	6.96	-	Saccharomyces cerevisiae (strain ATCC 204508 / S288c)
Carbonic anhydrase Enzyme	Ki	8	-	Candida albicans (strain SC5314 / ATCC MYA-2876)
Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase Enzyme	Ki	5.52	-	Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)
Carbonic anhydrase Enzyme	Ki	6.96	-	Candida glabrata (strain ATCC 2001 / CBS 138 / JCM 3761 / NBRC 0622 / NRRL Y-65)
Alpha carbonic anhydrase Enzyme	Ki	7.54	-	Stylophora pistillata
Carbonic anhydrase Enzyme	Ki	6.44	-	Stylophora pistillata
Carbonic anhydrase 2 Enzyme	Ki	6.43	-	Cryptococcus neoformans var. grubii
Astrosclerin-3 Enzyme	Ki	7.42	-	Astrosclera willeyana
Beta-carbonic anhydrase 1 Enzyme	Ki	6.21	-	Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)
Delta carbonic anhydrase Unclassified	Ki	6.41	-	Thalassiosira weissflogii
Carbonic anhydrase 2 Enzyme	Ki	6.32	-	Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)
GABA-A receptor alpha-1/beta-2/gamma-2 Ion channel	POSITIVE MODULATOR	-	-	Homo sapiens
Carbonic anhydrase V Enzyme	Ki	7.6	-	Homo sapiens
Glutamate receptor ionotropic kainate Ion channel	ANTAGONIST	-	-	Homo sapiens
Glutamate receptor ionotropic AMPA Ion channel	ANTAGONIST	-	-	Homo sapiens
Carbonic anhydrase, alpha family Unclassified	Ki	6.11	-	Hydrogenovibrio crunogenus (strain XCL-2)
Carbonate dehydratase Enzyme	Ki	8.18	-	Sulfurihydrogenibium sp. (strain YO3AOP1)

SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Seizure	2436	2469.945	10039906
Angle closure glaucoma	463	1607.877	10002500
Migraine	1025	882.747	10027599
Multiple-drug resistance	340	692.505	10048723
Myopia	228	668.155	10028651
Status epilepticus	458	657.464	10041962
Product substitution issue	441	630.261	10069326
Choroidal effusion	152	593.833	10063970
Nephrolithiasis	626	544.912	10029148
Epilepsy	513	533.439	10015037
Drug ineffective for unapproved indication	565	528.13	10051118
Drug ineffective	4215	520.829	10013709
Completed suicide	1147	500.632	10010144
Somnolence	1288	481.522	10041349
Intentional self-injury	396	401.951	10022524
Generalised tonic-clonic seizure	440	397.103	10018100
Suicidal ideation	629	389.431	10042458
Aggression	479	377.796	10001488
Renal tubular acidosis	165	372.118	10038535
Foetal exposure during pregnancy	659	367.377	10071404
Sedation	470	360.11	10039897
Visual perseveration	64	337.171	10073653
Memory impairment	715	328.066	10027175
Paraesthesia	914	317.764	10033775
Hyperammonaemic encephalopathy	152	309.011	10067327
Cognitive disorder	516	305.987	10057668
Hyperammonaemia	210	305.39	10020575
Intentional overdose	622	302.802	10022523
Heat stroke	112	294.226	10019345
Joint swelling	142	286.979	10023232
Depression	1059	285.858	10012378
Febrile neutropenia	44	279.145	10016288
Anaemia	261	277.324	10002034
Pemphigus	13	274.017	10034280
Metabolic acidosis	494	271.145	10027417
Petit mal epilepsy	157	268.105	10034759
Abortion spontaneous	345	259.335	10000234
Disturbance in attention	401	253.669	10013496
Synovitis	30	239.736	10042868
Irritability	361	232.668	10022998
Toxicity to various agents	1378	224.163	10070863
Hand deformity	17	221.301	10061194
Flat anterior chamber of eye	53	219.622	10016760
Exposure during pregnancy	703	217.44	10073513
Infusion related reaction	130	217.428	10051792
Product use in unapproved indication	1059	216.229	10076476
Acute kidney injury	364	215.98	10069339
Headache	2125	203.315	10019211
Acidosis hyperchloraemic	70	201.491	10000489
Glossodynia	38	201.316	10018388

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE IUPHAR/BPS 4 interactions

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

Target	Action	Affinity	PubMed
carbonic anhydrase 1 CA1	Inhibition	6.599999904632568 pKi	15686894
carbonic anhydrase 12 CA12	Inhibition	8.420000076293945 pKi	15686894
carbonic anhydrase 4 CA4	Inhibition	7.369999885559082 pKi	16039848
carbonic anhydrase 7 CA7	Inhibition	9.050000190734863 pKi	23965175

SOURCE PharmGKB 19 phenotype rows

Pharmacogenomics

Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.

SCN2A (PA35004) rs2304016

Allele A is associated with drug resistance when treated with carbamazepine, lamotrigine, oxcarbazepine, phenytoin or topiramate in people with Epilepsy as compared to allele G.

Evidence: -; PMID 18784617

GRIK1 (PA28973) rs2832407

Genotypes AA + AC is associated with decreased response to topiramate in people with Alcohol-Related Disorders as compared to genotype CC.

Evidence: -; PMID 19331489

GRIK1 (PA28973) rs2832407

Genotypes AA + AC is associated with increased concentrations of topiramate in people with Alcohol-Related Disorders as compared to genotype CC.

Evidence: -; PMID 19331489

CA12 (PA25987) rs2306719

Genotype TT is associated with decreased serum bicarbonate levels when treated with topiramate and zonisamide as compared to genotype CT.

Evidence: -; PMID 21278619

CA12 (PA25987) rs4984241

Genotype AA is associated with decreased serum bicarbonate levels when treated with topiramate and zonisamide as compared to genotype GG.

Evidence: -; PMID 21278619

GABRA1 (PA28489) rs6892782

Genotype CC is not associated with response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype TT.

Evidence: -; PMID 24236484

GABRA1 (PA28489) rs1157122

Genotype CC is not associated with response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype TT.

Evidence: -; PMID 24236484

GABRA1 (PA28489) rs10068980

Genotype AA is not associated with response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype GG.

Evidence: -; PMID 24236484

GABRA3 (PA28491) rs1112122

Genotype GG is not associated with response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype TT.

Evidence: -; PMID 24236484

GABRA3 (PA28491) rs4828696

Genotype TT is not associated with increased response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype CC.

Evidence: -; PMID 24236484

INSR (PA202) rs2396185

Allele C is associated with increased response to topiramate as compared to genotype AA.

Evidence: -; PMID 26524290

GABRA1 (PA28489) rs6883877

Genotype CT is not associated with increased response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype CC.

Evidence: -; PMID 24236484

- rs511310

Genotype GG is not associated with decreased response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype AA.

Evidence: -; PMID 24236484

INSR rs2396185

Evidence: 3; PMID 1

SCN2A rs2304016

Epilepsy

Evidence: 3; PMID 1

CA12 rs4984241

Evidence: 3; PMID 1

CA12 rs2306719

Evidence: 3; PMID 1

GRIK1 rs2832407

Alcohol-Related Disorders

Evidence: 3; PMID 1

ABCB1 rs1045642

Migraine with Aura;Migraine without Aura

Evidence: 3; PMID 1

SOURCE NLM RxNorm 4 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
TOPIRAMATE	38404	SU	MTHSPL
Topiramate	38404	SU	MTHSPL
topiramate	38404	IN	RXNORM
Topamax	220343	BN	RXNORM

SOURCE SIDER 80 side-effect rows

Side Effects

SIDER side-effect terms mapped to the drug or same-CAS compound identity.

Side Effect	Drug Name	MedDRA Type	Concept ID
Abdominal discomfort	topiramate	LLT	C0232487
Abdominal discomfort	topiramate	PT	C0232487
Abdominal discomfort	topiramate	PT	C0232487
Abdominal distension	topiramate	LLT	C0000731
Abdominal distension	topiramate	PT	C0000731
Abdominal distension	topiramate	PT	C0000731
Abdominal pain	topiramate	LLT	C0000737
Abdominal pain	topiramate	PT	C0000737
Abdominal pain lower	topiramate	LLT	C0232495
Abdominal pain lower	topiramate	PT	C0232495
Abdominal pain upper	topiramate	LLT	C0232492
Abdominal pain upper	topiramate	PT	C0232492
Abdominal tenderness	topiramate	LLT	C0232498
Abdominal tenderness	topiramate	PT	C0232498
Abnormal behaviour	topiramate	LLT	C0233514
Abnormal behaviour	topiramate	PT	C0233514
Abnormal sensation in eye	topiramate	LLT	C0497201
Abnormal sensation in eye	topiramate	PT	C0497201
Abnormal vision	topiramate	LLT	C3665386
Accommodation disorder	topiramate	LLT	C0152198
Accommodation disorder	topiramate	PT	C0152198
Acidosis	topiramate	LLT	C0001122
Acidosis	topiramate	PT	C0001122
Acidosis hyperchloraemic	topiramate	LLT	C0085569
Acidosis hyperchloraemic	topiramate	PT	C0085569
Acne	topiramate	LLT	C0702166
Acne	topiramate	PT	C0702166
Action tremor	topiramate	LLT	C0234376
Action tremor	topiramate	PT	C0234376
Administration site reaction	topiramate	LLT	C0851536
Administration site reaction	topiramate	PT	C0851536
Affect lability	topiramate	PT	C0233472
Affect lability	topiramate	LLT	C0233472
Affect lability	topiramate	PT	C0233472
Ageusia	topiramate	LLT	C2364111
Ageusia	topiramate	PT	C2364111
Aggression	topiramate	LLT	C0001807
Aggression	topiramate	PT	C0001807
Aggression	topiramate	PT	C0001807
Aggressive reaction	topiramate	LLT	C1457883
Agitation	topiramate	LLT	C0085631
Agitation	topiramate	PT	C0085631
Agitation	topiramate	PT	C0085631
Agranulocytosis	topiramate	LLT	C0001824
Agranulocytosis	topiramate	PT	C0001824
Akinesia	topiramate	LLT	C0085623
Akinesia	topiramate	PT	C0085623
Alanine aminotransferase increased	topiramate	LLT	C0151905
Alanine aminotransferase increased	topiramate	PT	C0151905
Albuminuria	topiramate	LLT	C0001925
Albuminuria	topiramate	PT	C0001925
Alcohol intolerance	topiramate	LLT	C0151474
Alcohol intolerance	topiramate	PT	C0151474
Alkaline phosphatase serum increased	topiramate	LLT	C0750857
Allergic oedema	topiramate	LLT	C0847033
Allergic oedema	topiramate	PT	C0847033
Alopecia	topiramate	LLT	C0002170
Alopecia	topiramate	PT	C0002170
Altered state of consciousness	topiramate	PT	C0150450
Altered visual depth perception	topiramate	LLT	C1096444
Altered visual depth perception	topiramate	PT	C1096444
Amblyopia	topiramate	LLT	C0002418
Amblyopia	topiramate	PT	C0002418
Amenorrhoea	topiramate	LLT	C0002453
Amenorrhoea	topiramate	PT	C0002453
Amnesia	topiramate	LLT	C0002622
Amnesia	topiramate	PT	C0002622
Anaemia	topiramate	LLT	C0002871
Anaemia	topiramate	PT	C0002871
Anger	topiramate	LLT	C0002957
Anger	topiramate	PT	C0002957
Angina pectoris	topiramate	LLT	C0002962
Angina pectoris	topiramate	PT	C0002962
Angiopathy	topiramate	LLT	C0042373
Angiopathy	topiramate	PT	C0042373
Angle closure glaucoma	topiramate	LLT	C0017605
Angle closure glaucoma	topiramate	PT	C0017605
Anhidrosis	topiramate	LLT	C0003028
Anhidrosis	topiramate	PT	C0003028
Anorexia	topiramate	LLT	C0003123

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Topiramate used for in pharmaceutical contexts?

Topiramate (CAS 97240-79-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Topiramate?

Topiramate has 7,885 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Seizure, Angle closure glaucoma, Migraine, Multiple-drug resistance, Myopia. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Topiramate also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Topiramate with EU status "permitted".

What clinical phase is Topiramate in?

Topiramate is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Topiramate?

Topiramate has 44 bioactivity rows in this page query. Rendered target entries include Sodium channel protein type 5 subunit alpha, Sodium channel protein type 1 subunit alpha, Nuclear receptor subfamily 1 group I member 2, Carbonic anhydrase 2, Carbonic anhydrase 1.